The United States of America, As Represented by the Secretary, Department of Health and Human Services

The United States of America As Represented by the Department of Health

Other

The United States of America As Represented by the Secretary of

Royal Cornwall Hospital Trust

Novavax, Inc.

Ann W. Funkhouser

Suzanne U. Emerson

Robert H. Purcell

Eric D'hondt

Suzanne U Emerson

Robert H Purcell

Zhaochun Chen

Sergei A Tsarev

Stephen H Leppla

Jens Bukh

Mahtab Moayeri

Darren J Schofield

Masayuki Yanagi

Bernard Moss

Patricia L Earl

Ann W Funkhouser

Eric D'Hondt

Stephen M Feinstone

Jeffrey I Cohen

Robin A Robinson

John R Ticehurst

Priyanka Shukla

Hanh T Nguyen

Harry R Dalton

Richard Bendall

Xiang-Jin Meng

Jonathan E Silver

Ian D Gust

Richard J Daemer

Harvey J Alter

Sergie A Tsarev

Michael S Balayan

Akito Sakai

Robert Purcell, Ii

Jae-Hwan Nam

Gopa Raychaudhuri

Deneen Stewart

Tina S Morris

Stephan M Feinstone

Czeslaw Wychowski

Richard P Bendall

The present invention relates to monoclonal antibodies that bind or neutralize anthrax protective antigen (PA) toxin. The invention provides such antibodies, fragments of such antibodies retaining anthrax PA toxin-binding ability, fully human or humanized antibodies retaining anthrax PA toxin-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.

Monoclonal antibodies that neutralize anthrax protective antigen (PA) toxin

The present invention relates to monoclonal antibodies that bind or neutralize anthrax lethal factor (LF), edema factor (EF), and/or protective antigen (PA). The invention provides such antibodies, fragments of such antibodies retaining anthrax toxin-binding ability, fully human or humanized antibodies retaining anthrax toxin-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.

Monoclonal antibodies that neutralize anthrax toxins

The invention relates to the discovery of an HEV strain from a chronically infected patient. The virus grow unusually well in numerous cell cultures. Thus, the invention provides cell cultures, vectors, and vaccine compositions based on the virus.

Infectious hepatitis E virus genotype 3 recombinants

The present invention relates to monoclonal antibodies that bind or neutralize Orthopoxviruses. The invention provides such antibodies, fragments of such antibodies retaining B5 or A33 binding ability, fully human antibodies retaining B5 or A33 binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.

Monoclonal antibodies against orthopoxviruses

The invention relates to the discovery of an HEV strain from a chronically infected patient. The virus grow unusually well in numerous cell cultures. Thus, the invention provides cell cultures, vectors, and vaccine compositions based on the virus. The invention relates, in part, on the identification of a new strain of HEV genotype 3 virus. Strain Kernow-C1 (genotype 3) of HEV, which was isolated from a chronically infected patient, was used to identify human, pig and deer cell lines permissive for infection. Adaptation of the Kernow-C 1 strain to growth in human hepatoma cells selected for a rare virus recombinant that contained an insertion of 174 ribonucleotides (58 amino acids) of a human ribosomal protein gene and additional mutations.

Monoclonal antibodies against Orthopoxviruses

The present invention discloses nucleic acid sequences which encode infectious hepatitis C viruses and the use of these sequences, and polypeptides encoded by all or part of these sequences, in the development of vaccines and diagnostics for HCV and in the development of screening assays for the identification of antiviral agents for HCV.

Cloned genomes of infectious hepatitis C viruses and uses thereof

Embodiments described herein include nucleic acid sequences, which encode hepatitis C virus of strain HC-TN, genotype 1a, proteins and polypeptides and fragments thereof. Use of these compositions, and diagnostics for HCV and in the development of screening assays for the identification of antiviral agents for HCV are also contemplated.

Cloned genome of infectious hepatitis C virus strain HC-TN and uses thereof

Growing community of inventors

Gaithersburg, MD, United States of America

Suzanne U Emerson